Hims & Hers Health (HIMS) Stock Jumps on Policy Tailwinds and Buyback Momentum

Hims & Hers Health Inc. (NYSE: HIMS) ended Monday’s U.S. session sharply higher, extending a volatile but strongly positive year for the fast‑growing telehealth platform.

Below is a news-style, SEO-optimized breakdown of Hims & Hers Health (HIMS) stock today (24.11.2025), the fresh catalysts moving the share price, and the key fundamentals and risks investors are watching.

HIMS stock today: price, performance and key metrics

As of the close on Monday, November 24, 2025, Hims & Hers Health stock traded around $37.8 per share, up roughly 8.8% on the day from a previous close near $34.7. ^[1]

Intraday, the stock saw wide swings, trading roughly between the mid‑$34s and the high‑$38s, on volume of about 20–21 million shares, roughly in line with its already high average daily volume of ~28.6 million. ^[2]

Other notable snapshot metrics today:

Year-to-date performance: Up about 38% so far in 2025. ^[3]
52‑week range: Approximately $24 to $73, underlining how volatile HIMS has been over the past year. ^[4]
Market cap: Around $8 billion, depending on the data source and share count used. ^[5]
Valuation: Shares are trading at a rich earnings multiple – most sources put trailing P/E well above 60x, signaling that the market still prices HIMS as a high‑growth story rather than a mature value stock. ^[6]
Short interest: Around 33% of the float is sold short, an unusually high level that can amplify both rallies and sell‑offs. ^[7]

With that backdrop, investors are asking: why is Hims & Hers stock up today, and can the move last?

Why Hims & Hers Health (HIMS) stock is rising on November 24, 2025

Today’s jump in HIMS stock comes from a mix of policy headlines, options-market positioning, and follow‑through from recent corporate news.

1. Obamacare subsidy headlines lift healthcare names

A key near‑term catalyst came from Washington.

A Politico report indicated that the White House is preparing to pitch a two‑year extension of enhanced Affordable Care Act (“Obamacare”) subsidies, which are currently set to expire at the end of the year. The proposal, as summarized by StockStory/TradingView, would extend subsidies and expand eligibility for households earning up to around 700% of the federal poverty line. ^[8]

That headline sparked a broad rally across healthcare names tied to the ACA ecosystem. In a mid‑day recap, StockStory noted that Hims & Hers Health shares were up about 6.2% alongside gains in Alignment Healthcare, Guardant Health and others, with investors betting that more generous subsidies support enrollment and spending on digital and managed-care offerings. ^[9]

Although Hims & Hers isn’t a traditional insurer, the market is clearly treating it as part of the “healthcare access and affordability” trade, which can benefit when policy moves underpin consumer demand for modern, lower‑friction care.

2. Options and sentiment tailwinds

A separate piece of real‑time options data also helps explain the move.

According to a TipRanks note published today, HIMS shares have seen: ^[10]

A decline in the put/call ratio, meaning fewer bearish bets relative to bullish call options.
Lower implied volatility, suggesting reduced expectations for extreme downside.
A technical “Hold” signal, with the platform highlighting a market cap near $7.9 billion, average volume around 28.6 million shares, and year‑to‑date gains of roughly 37.7%.

Taken together, the options setup points to a market that is still cautious but incrementally less afraid of near‑term downside, especially now that the company has just reaffirmed strong growth in its latest quarter and bolstered its capital return plans.

3. Fresh fundamental narratives: “growth beyond GLP‑1s”

On the fundamental side, a new Seeking Alpha article published this morning argues that Hims & Hers’ growth story is not just about GLP‑1 weight-loss drugs. The author highlights the company’s broader platform expansion, newer offerings like Labs, continued vertical integration and ambitious long‑term revenue targets, while also noting that free cash flow growth may moderate as management reinvests. ^[11]

Even though that article is opinion rather than news, it contributes to a narrative that HIMS is more than just a “weight-loss trade”, which matters as regulators and the public scrutinize GLP‑1 marketing.

4. Policy and reputational overhang: GLP‑1 marketing in the spotlight

That scrutiny is front and center today thanks to a Bloomberg feature on how telehealth platforms are marketing GLP‑1 obesity drugs to people who are not medically obese. The story describes a surge of online ads promising rapid weight loss, sometimes pitched as “microdosing” copycat Ozempic for cosmetic reasons rather than true medical need. ^[12]

While the piece does not single out Hims & Hers alone, it implicitly includes the company in a cohort of telehealth providers whose GLP‑1 marketing may face tougher regulatory oversight going forward. For now, investors seem comfortable that Hims & Hers’ growing regulatory bench (more on that below) and diversified product mix can manage that risk, but it remains a critical medium‑term issue.

5. Small insider selling filing

Finally, there was also a Form 144 filing today: officer Soleil Boughton submitted notice to the SEC for a potential sale of 2,631 shares of HIMS stock, to be executed via Fidelity under a pre‑arranged 10b5‑1 trading plan. ^[13]

The amount is tiny relative to Hims & Hers’ >200 million share float and appears routine, so the market has largely shrugged it off.

Under the hood: Q3 2025 results and growth outlook

Today’s move doesn’t happen in a vacuum. It builds on a strong but complex third quarter, reported earlier this month.

Explosive revenue and subscriber growth

In its Q3 2025 earnings release, Hims & Hers posted: ^[14]

Total revenue of about $599 million, up 49% year over year.
Online revenue of ~$589 million, up 50%; wholesale revenue contributed around $9.9 million.
Net income of roughly $15.8 million, up sharply year on year (though last year benefited from a large tax valuation allowance release).
Adjusted EBITDA of $78.4 million, up about 53% vs. Q3 2024.
Free cash flow of $79.4 million and operating cash flow of $148.7 million, both substantially higher than a year ago.

On the customer side, growth remains robust:

Subscribers reached about 2.47 million, a 21% year‑over‑year increase.
Monthly online revenue per average subscriber rose to about $80, up roughly 19% from $67 a year earlier.

That combination — more users and more revenue per user — is exactly what growth investors want from a digital‑health platform.

Guidance and GLP‑1 opportunity

For full‑year 2025, Hims & Hers guided to: ^[15]

Revenue of $2.335–$2.355 billion, implying strong double‑digit growth.
Adjusted EBITDA of $307–$317 million, or roughly a 13% margin.

For Q4 2025, the company expects revenue of $605–$625 million and adjusted EBITDA of $55–$65 million, implying margins of 9–10% as it steps up investment in new capabilities.

A big part of the growth story is GLP‑1 weight-loss therapy:

In its earnings coverage, Reuters noted that Hims & Hers’ Q3 revenue of about $600 million beat Wall Street estimates around $580 million, driven by a 21% increase in subscribers and a jump in revenue per user. ^[16]
Management reiterated a long‑term revenue target of around $6.5 billion by 2030, leaning heavily on GLP‑1 and metabolic health services, and suggested the GLP‑1 segment alone could contribute hundreds of millions in revenue by 2026. ^[17]
The company is in active talks with Novo Nordisk to offer branded Wegovy injections and a future oral formulation on its platform, though there is no finalized agreement yet. ^[18]

In short, fundamentals remain very growth‑oriented, but with a heavier dependence on regulatory‑sensitive GLP‑1 categories.

Strategic moves in 2025: Labs, menopause, and international expansion

Hims & Hers has also been busy broadening its business beyond weight loss and sexual health.

Labs: a new recurring-revenue pillar

On November 13, 2025, the company launched Hims & Hers Labs, a new subscription‑style lab testing product. ^[19]

Key points from the announcement:

Labs offers proactive, doctor‑designed testing programs covering heart health, metabolism, hormones, inflammation, stress, and more.
Customers can choose between two annual plans:
- Base plan: One blood draw per year with about 50 biomarker tests across nine categories, priced at $199/year.
- Advanced plan: Two blood draws per year with 120+ biomarkers across 10 categories, priced at $499/year.
Test results feed into doctor‑developed action plans and, where appropriate, personalized treatment regimens, including lifestyle guidance and prescription therapies.

Labs fits Hims & Hers’ push toward “data‑driven, preventive care” and creates another potential recurring revenue stream that isn’t tied to GLP‑1 cycles.

New leadership in policy and regulation

On November 17, 2025, Hims & Hers named Deb Autor as its first Chief Policy Officer, a new C‑suite role overseeing global public policy, regulatory and government affairs. ^[20]

Autor brings more than three decades of regulatory experience, including senior roles at the FDA, the U.S. Department of Justice, and AstraZeneca. Her appointment signals that Hims & Hers is preparing for a tougher regulatory environment, especially around telehealth prescribing, GLP‑1s, and data privacy.

Canada GLP‑1 expansion on deck

Earlier this year, the company also announced plans to bring its weight-loss program to Canada in 2026, timed with the first‑ever availability of generic semaglutide there. ^[21]

The plan is to offer more affordable GLP‑1 treatment options, paired with 24/7 provider access and personalized care plans. That international move could open up another large market if execution goes well.

What the new $250 million buyback means for HIMS shareholders

Another big driver behind recent sentiment — and a key point mentioned in today’s TipRanks note — is Hims & Hers’ expanded share repurchase program. ^[22]

On November 13, 2025, the Board authorized a new “2025 Share Repurchase Program” of up to $250 million in Class A common stock, running through November 11, 2028. Highlights from the 8‑K and press release:

The program allows buybacks via open market purchases, private transactions, and Rule 10b5‑1 plans, at management’s discretion.
It replaces a prior $100 million program launched in July 2024, which has now been fully utilized.
Between October 1 and November 7, 2025, Hims & Hers repurchased roughly 1.33 million shares for about $55.5 million, finishing off the earlier authorization. ^[23]

For investors, the new buyback:

Signals confidence from management and the Board that HIMS shares are attractive at current levels.
Provides a downside cushion if volatility persists — especially important given the high short interest.
Could gradually reduce the share count, boosting EPS growth if the company maintains its earnings trajectory.

Of course, buybacks are only as good as the underlying execution; the program is discretionary and can be suspended or discontinued.

Risks to watch: GLP‑1 scrutiny, rich valuation and insider selling

Despite the bullish move, HIMS stock is far from risk‑free. Key issues include:

Regulatory and reputational risk around GLP‑1s
- Today’s Bloomberg story underscores growing concern that telehealth firms are marketing obesity drugs too aggressively, targeting people who may not meet medical guidelines. ^[24]
- Given Hims & Hers’ prominent role in GLP‑1 prescribing, tighter rules or more negative headlines could pressure growth and margins.
High valuation and execution demands
- A trailing P/E north of 60x (and even higher on some measures) leaves little room for disappointment on revenue, subscriber growth, or margins. ^[25]
- Management’s long‑term revenue and profit targets assume sustained high growth and successful expansion into multiple new lines (Labs, hormone health, international GLP‑1 markets, etc.).
Short interest and volatility
- With about one‑third of the float sold short, HIMS is structurally volatile. Rallies like today’s can be amplified by short covering, but the same dynamic can magnify downside if sentiment flips. ^[26]
Insider sales and governance optics
- Today’s Form 144 for 2,631 shares is small, but investors will keep monitoring Form 4 and 144 filings for signs of bigger insider selling. ^[27]

How Wall Street values Hims & Hers Health (HIMS) now

Analyst opinion remains mixed and cautious, even after today’s rally.

MarketBeat aggregates 15 analyst ratings over the past 12 months and assigns HIMS a consensus rating of “Reduce” (effectively between Sell and Hold), with:
- 3 Sell ratings
- 10 Hold ratings
- 2 Buy ratings
  The average 12‑month price target is about $45.27, implying roughly 20% upside from today’s closing price, with a wide range from $30 to $85 per share. ^[28]
StockAnalysis.com, using a smaller analyst set, also shows a “Hold” consensus and an average price target around $44.6, again suggesting mid‑teens to ~20% upside if Wall Street’s forecasts prove correct. ^[29]
Moomoo’s forecast tool, updated November 19, cites 10 analysts over the last three months, with a Hold consensus (20% Buy, 60% Hold, 20% Sell) and an average target around $48.6, with the same $30–$85 range. ^[30]

In other words, Wall Street likes the growth story but worries about valuation and GLP‑1 risk — a stance that lines up with many retail investors’ debates on social platforms.

FAQ: Hims & Hers Health (HIMS) stock today

Why is Hims & Hers Health (HIMS) stock up today?
Because of a policy-fueled healthcare rally tied to potential Obamacare subsidy extensions, improving options‑market sentiment, and continued enthusiasm for Hims & Hers’ growth initiatives and share buyback program. ^[31]

What is HIMS stock price today?
Hims & Hers Health stock closed around $37.8 on November 24, 2025, up about 8.8% on the day, after trading between roughly the mid‑$34s and high‑$38s. ^[32]

Is HIMS stock cheap or expensive?
By traditional metrics like P/E, HIMS is expensive, trading at well above 60x trailing earnings, and relies on continued high growth to justify that multiple. However, bulls argue that the company’s rapid revenue and subscriber growth, plus new initiatives like Labs and international GLP‑1 expansion, make the valuation reasonable over a multi‑year horizon. ^[33]

What are the biggest risks for Hims & Hers stock?
Key risks include regulatory scrutiny of GLP‑1 prescribing and telehealth marketing, potential pressures from competitors such as Novo Nordisk, execution risk on ambitious revenue and margin goals, and the stock’s high volatility and heavy short interest. ^[34]

Bottom line: how to think about HIMS after today’s rally

For news readers and investors tracking Hims & Hers Health stock today:

Bullish case:
- Rapid revenue and subscriber growth.
- New product pillars in Labs, menopause and hormone health, and international GLP‑1 programs. ^[35]
- A sizable $250 million buyback and a new Chief Policy Officer strengthen both capital allocation and regulatory strategy. ^[36]
Bearish case:
- Dependence on GLP‑1 and telehealth prescribing in an environment of rising regulatory and political scrutiny. ^[37]
- A valuation that already prices in a lot of good news.
- High volatility and large short interest that can intensify both gains and losses.

Nothing in this article is financial advice. If you’re considering investing in Hims & Hers Health (HIMS), it’s important to review the company’s latest SEC filings, earnings transcripts, and risk factors, and to consult a qualified financial advisor who understands your specific situation.

Why is Hims & Hers Stock Falling, and Should Investors Buy the Dip? | HIMS Stock Analysis